These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35664758)

  • 1. Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States.
    Zakharia Y; Thomaidou D; Li B; Siu G; Levin R; Vlahiotis A; Rao D; Zanotti G
    Front Oncol; 2022; 12():861189. PubMed ID: 35664758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab + axitinib vs. ipilimumab + nivolumab.
    Shah NJ; Sura SD; Shinde R; Shi J; Singhal P; Perini RF; Motzer RJ
    Urol Oncol; 2023 Nov; 41(11):459.e1-459.e8. PubMed ID: 37722984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma.
    Du EX; Betts KA; Wang T; Kitchen SA; He X; Yin X; Guttenplan SB; Beauchamp K; Delgado A; Rosenblatt L
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39127872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
    Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
    Ding D; Hu H; Shi Y; She L; Yao L; Zhu Y; Zeng S; Shen L; Huang J
    Oncologist; 2021 Feb; 26(2):e290-e297. PubMed ID: 32918790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis.
    Cao G; Wu X; Wang Z; Tian X; Zhang C; Wu X; Zhang H; Jing G; Yan T
    BMJ Open; 2020 Aug; 10(8):e034626. PubMed ID: 32859659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    Rini BI; Plimack ER; Stus V; Gafanov R; Hawkins R; Nosov D; Pouliot F; Alekseev B; Soulières D; Melichar B; Vynnychenko I; Kryzhanivska A; Bondarenko I; Azevedo SJ; Borchiellini D; Szczylik C; Markus M; McDermott RS; Bedke J; Tartas S; Chang YH; Tamada S; Shou Q; Perini RF; Chen M; Atkins MB; Powles T;
    N Engl J Med; 2019 Mar; 380(12):1116-1127. PubMed ID: 30779529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
    Harada KI; Sato R; Bando Y; Sano A; Matsushita Y; Tamura K; Terakawa T; Furukawa J; Fujimoto N; Fujisawa M; Miyake H
    Int J Urol; 2023 Sep; 30(9):772-777. PubMed ID: 37345413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
    Watson TR; Gao X; Reynolds KL; Kong CY
    JAMA Netw Open; 2020 Oct; 3(10):e2016144. PubMed ID: 33052401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib and Axitinib After Vascular Endothelial Growth Factor Therapy in Patients with Advanced Renal Cell Carcinoma: A Retrospective Cohort Study from England.
    Brown J; Harrow B; Marciniak A; McCarthy C; Houchard A; Cirneanu L; Protheroe A
    Drugs Real World Outcomes; 2024 Jun; 11(2):195-207. PubMed ID: 38265633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma.
    Bensimon AG; Zhong Y; Swami U; Briggs A; Young J; Feng Y; Song Y; Signorovitch J; Adejoro O; Chakravarty A; Chen M; Perini RF; Geynisman DM
    Curr Med Res Opin; 2020 Sep; 36(9):1507-1517. PubMed ID: 32697113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
    Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
    Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
    Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
    Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor.
    Zakharia Y; Huynh L; Du S; Chang R; Pi S; Sundaresan S; Duh MS; Zanotti G; Thomaidou D
    Clin Genitourin Cancer; 2023 Oct; 21(5):e343-e351. PubMed ID: 37087399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma.
    Black CM; Hanna GJ; Wang L; Ramakrishnan K; Goto D; Turzhitsky V; Hair GM
    Front Oncol; 2023; 13():1160144. PubMed ID: 37284189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study.
    El Zarif T; Semaan K; Xie W; Eid M; Zarba M; Issa W; Zhang T; Nguyen CB; Alva A; Fahey CC; Beckermann KE; Karam JA; Campbell MT; Procopio G; Stellato M; Buti S; Zemankova A; Melichar B; Massari F; Mollica V; Venugopal B; Ebrahimi H; de Velasco G; Gurney HP; De Giorgi U; Parikh O; Winquist E; Master V; Garcia AR; Cutuli HJ; Ferguson TR; Gross-Goupil M; Baca SC; Pal SK; Braun DA; McKay RR; Heng DYC; Choueiri TK
    Eur Urol; 2024 Aug; ():. PubMed ID: 39147674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
    Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study on the evolution of systemic treatments for advanced renal cell carcinoma in Southwest Finland between 2010 and 2021.
    Hölsä O; Teittinen K; Anttalainen A; Ukkola-Vuoti L; Summanen M; Mattila KE
    Ther Adv Urol; 2023; 15():17562872231206243. PubMed ID: 37941979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.